Project Grant R01EY037664
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support (CFDA 93.310) program provides $498,248 to the University of Connecticut Health Center (UCHC) to investigate the molecular mechanisms underlying corneal and retinal injury caused by exposure to chemical threat agents like nitrogen mustard. The key objectives are to: 1) Examine the role of the p53-PAD axis in driving corneal hypercitrullination, a pathological response, after nitrogen...
- This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $295,500.00 to The Schepens Eye Research Institute, Inc. to develop a neuropeptide-based countermeasure to mitigate ocular damage from exposure to mustard gas agents. The research aims to assess the therapeutic efficacy of topical alpha-melanocyte-stimulating hormone (α-MSH) treatment in preventing corneal damage, nerve loss, and inflammation in a mouse model of...
- This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) will provide $937,468 to Northwestern University to understand the pathological mechanisms of sulfur mustard gas keratopathy (MGK) in the cornea. The research aims to explore how corneal mustard exposure induces autophagy, a cellular process that can play detrimental roles, via liberating the protein Beclin1 from the Beclin1-Bcl2 complex. The project will conduct in vitro and in...
- This Project Grant award by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $583,250 to The Schepens Eye Research Institute, Inc. to identify the mechanisms underlying ocular toxicity caused by nitrogen mustard exposure and evaluate specialized lipid mediators as potential medical countermeasures. The key objectives are to: 1) Determine how nitrogen mustard alters the function of conjunctival goblet cells and if...
- This Project Grant award from the National Institutes of Health's (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $780,000 to the University of Chicago to study the mechanisms of skin damage caused by chemical weapons exposure. The research aims to understand how skin vesicants disrupt cell adhesion and the underlying cytoskeletal dynamics, which could lead to the development of more effective medical countermeasures. Key objectives include investigating the role of the...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $1,434,104 to the University of Texas Medical Branch at Galveston (UTMB) to investigate the role of the protein SIRT6 in mitigating corneal and retinal injury caused by exposure to the highly toxic chemical acrolein. The 3-year project aims to characterize the pathological changes in the cornea and retina following acrolein exposure using a newly developed...
- This federal Project Grant award, valued at $1,593,795.00 and awarded on July 15, 2025, supports the "Exploration of Topical Amniotic Membrane of the Treatment of Ocular Chemical and Thermal Burn Injuries" research project. The grant was awarded by the Defense Health Agency, which administers the Military Medical Research and Development program (CFDA 12.420). The research is being conducted by the University of Illinois, a prominent public research institution in Chicago, Illinois....
- This Cooperative Agreement award from the National Eye Institute (CFDA 93.867 - Vision Research) aims to develop a novel fenofibrate-loaded microemulsion (FENO-ME) eyedrop as a non-steroid treatment for nitrogen mustard (NM)-induced corneal injury. The $22,677 award to Virginia Commonwealth University (VCU) spans from Sep 2025 to May 2030. The project seeks to: 1) Validate PPARα signaling as a drug target for NM-induced corneal injury and optimize the FENO-ME eyedrop formulation; 2)...
- The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,477,500 Project Grant to The Schepens Eye Research Institute, Inc., a non-profit organization affiliated with Harvard Medical School and Massachusetts Eye and Ear. The 3-year grant, awarded on September 1, 2023, will fund research on "Topical Calcitonin Gene-Related Peptide for Corneal Injury Prevention and Regeneration." The Schepens Eye Research Institute, which has...
- The University of Connecticut Health Center (UCHC) received a $1,182,528 Project Grant award from the Defense Health Agency to develop a multifunctional bandage lens and bioadhesive for the treatment of corneal wounds. This award, which runs from September 1, 2023 to August 31, 2026, is funded under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCHC's research to transform health care for Service Members and the American public through innovative and...
This Project Grant award from the Department of Health and Human Services' National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $1,467,198.00 to the University of Connecticut Health Center (UCHC) to investigate the cellular and molecular mechanisms of corneal and sensory nerve damage caused by exposure to chemical warfare agents. The key products and services to be delivered under this 3-year award, which runs from September 15, 2025 to August 31, 2028, include: Identifying proteins that are altered by the enzyme peptidyl arginine deiminase 4 (PAD4) through citrullination, and determining how these citrullinated proteins impact biological pathways and cellular processes in the corneal epithelium. Exploring a newly identified drug target in corneal Schwann cells and how its pharmacological inhibition can promote Schwann cell and sensory nerve regeneration following exposure to the chemical warfare agent nitrogen mustard. The research aims to provide a more comprehensive understanding of the structural and functional damage to the cornea and sensory nerves caused by exposure to chemical threat agents, with the goal of informing the development of improved medical countermeasures.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.5m | 9/10/25 |